Post-earnings recap
Reported
Thu, Jul 30, 2026
EPS actual
$2.85
EPS est.
$1.88
EPS surprise
+51.84%
1-day move
+2.61%
Neurocrine Biosciences reported strong earnings with an EPS that significantly exceeded expectations, leading to a 2.61% increase in stock price. However, revenue figures were not disclosed, leaving some uncertainty. The positive EPS surprise indicates strong performance in the company's operations, but without revenue details, investors may remain cautious.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.85 | $1.96 | +51.84% |
| Revenue | — | $890M | — |
No transcript is on record, so the analysis is based solely on numerical results.
Neurocrine Biosciences, Inc. is a biotechnology company focused on developing treatments for neurological and endocrine diseases. With a market cap of $15 billion, it plays a crucial role in the healthcare sector, particularly in addressing unmet medical needs in these specialized areas.
Last quarter
In Q1 2026, Neurocrine reported an EPS of $1.94, significantly beating estimates by 51.21%. The stock reacted positively, gaining 0.74% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+37.39%
Avg 1-day reaction
+1.33%
Analysts expect Neurocrine to continue its strong performance with an EPS of $1.96 and revenue of $890 million. The company has a history of beating earnings expectations, which adds to investor optimism.
Bull case
If Neurocrine exceeds the EPS estimate, it could signal strong demand for its products and effective cost management, potentially driving the stock higher.
Bear case
Conversely, if the company misses expectations, it may raise concerns about product demand or operational challenges, leading to a negative market reaction.
Key metrics to watch
EPS
$1.96Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
$890MTotal revenue reflects the company's sales performance and growth potential, which is vital for investor confidence.
The print will turn on these.
Q1
Will the EPS exceed $1.96, indicating continued strong performance?
A beat on EPS would reinforce the company's growth trajectory and operational efficiency.
Q2
What is the revenue outlook for the upcoming quarters?
Understanding revenue trends will provide insights into product demand and market positioning.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±7.0%
Why consensus could be wrong
The Street may underestimate the potential for Neurocrine to exceed EPS expectations due to strong product demand and effective cost management.
Supporting evidence
Neurocrine has consistently beaten EPS estimates in the past, indicating strong operational performance.
The options market is pricing a relatively modest move, suggesting that traders may not fully anticipate a significant upside.
Key risk
If revenue comes in significantly above $890 million, it could challenge the current consensus outlook.
Pre-commit to what would confirm each case.
This quarter's performance will be closely watched as it follows a strong history of earnings beats.
Bull confirmed if
An EPS of $2.00 or higher would confirm strong demand and effective cost management.
Bear confirmed if
An EPS below $1.90 could signal potential issues with product sales or operational challenges.
What the market is pricing for the move.
Implied Move
±3.78%
Historical Avg
±1.7%
The options market is pricing in a moderate move, suggesting that traders expect some volatility around the earnings announcement.
Options are pricing ±3.8% while NBIX has averaged ±1.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
33.4%
Smart-money positioning from the most recent 13F filings.
Institutional
102.86%
of float
Insider
1.06%
of float
Holders
1,126
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
13,711,607 sh · $2.0B
13.49%
2.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Neurocrine beats expectations, history suggests the stock could rise by around 2.03%, confirming strong operational performance.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss on earnings could lead to a decline, with historical patterns suggesting a potential drop of around 2.44%.
The lines on the call that would change the story.
JPMORGAN CHASE & CO
6,398,674 sh · $918.0M
6.29%
17.6%
Dodge & Cox Inc.
5,584,707 sh · $801.2M
5.49%
2.3%
Vanguard Portfolio Management LLC
4,974,083 sh · $713.6M
4.89%
5.2%
Vanguard Capital Management LLC
4,545,339 sh · $652.1M
4.47%
0.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.